Staging and prognosis of cutaneous melanoma

Surgical Oncology Clinics of North America

Volumn 20, Issue 1, 2011, Pages 1-17

  Dickson, Paxton V ^a   Gershenwald, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Melanoma; Prognosis; Staging

Indexed keywords

CANCER CLASSIFICATION; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; DATA BASE; DISEASE MARKER; DISTANT METASTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MITOSIS RATE; PHENOTYPE; PREDICTION; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TUMOR VOLUME; ULCER;

DATABASES, FACTUAL; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONALITY; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 78649460689     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.09.007     Document Type: Review

References (76)

1. Balch C.M., Murad T.M., Soong S.J., et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978, 188:732.
2. Eldh J., Boeryd B., Peterson L.E. Prognostic factors in cutaneous malignant melanoma in stage I. A clinical, morphological and multivariate analysis. Scand J Plast Reconstr Surg 1978, 12:243.
3. Van Der Esch E.P., Cascinelli N., Preda F., et al. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981, 48:1668.
4. Buzaid A.C., Ross M.I., Balch C.M., et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997, 15:1039.
5. Gershenwald J.E., Buzaid A.C., Ross M.I. Classification and staging of melanoma. Hematol Oncol Clin North Am 1998, 12:737.
6. Ross M. Modifying the criteria of the American Joint Commission on Cancer staging system in melanoma. Curr Opin Oncol 1998, 10:153.
7. Thompson J.F., Shaw H.M., Hersey P., et al. The history and future of melanoma staging. J Surg Oncol 2004, 86:224.
8. Balch C.M. Melanoma of the skin. AJCC cancer staging manual 2009, 325-344. Springer Verlag, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
9. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199.
10. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635.
11. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622.
12. Cormier J.N., Xing Y., Feng L., et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006, 106:2012.
13. Lee C.C., Faries M.B., Wanek L.A., et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008, 26:535.
14. Azzola M.F., Shaw H.M., Thompson J.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003, 97:1488.
15. Barnhill R.L., Katzen J., Spatz A., et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005, 32:268.
16. Busam K.J. The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. Ann Surg Oncol 2004, 11:360.
17. Gimotty P.A., Elder D.E., Fraker D.L., et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007, 25:1129.
18. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902.
19. Balch C.M., Soong S., Ross M.I., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup melanoma surgical trial. Ann Surg Oncol 2000, 7:87.
20. Breslow A., Cascinelli N., van der Esch E.P., et al. Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori 1978, 64:273.
21. Shaw H.M., Balch C.M., Soong S.J., et al. Prognostic histopathological factors in malignant melanoma. Pathology 1985, 17:271.
22. Buttner P., Garbe C., Bertz J., et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995, 75:2499.
23. Balch C.M., Wilkerson J.A., Murad T.M., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980, 45:3012.
24. McGovern V.J., Shaw H.M., Milton G.W., et al. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982, 6:399.
25. Salman S.M., Rogers G.S. Prognostic factors in thin cutaneous malignant melanoma. J Dermatol Surg Oncol 1990, 16:413.
26. Sondak V.K., Taylor J.M., Sabel M.S., et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004, 11:247.
27. Caudle AS, Ross MI, Prieto VG, et al. Mitotic rate predicts sentinel lymph node involvement in melanoma: impact of the 7th edition AJCC melanoma staging system. In: Society of surgical oncology 63rd annual cancer symposium. St. Louis (MO); 2010. p. S8.
28. Clark W.H., From L., Bernardino E.A., et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705.
29. Breslow A. Tumor thickness in evaluating prognosis of cutaneous melanoma. Ann Surg 1978, 187:440.
30. Morton D.L., Davtyan D.G., Wanek L.A., et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993, 71:3737.
31. Vollmer R.T. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu 1989, 24(Pt 1):383.
32. Gershenwald J.E., Hwu P. Melanoma. Cancer medicine 2010, 1459-1486. People's Medical Publishing House-USA, Shelton (CT). 8th edition. W.K. Hong, R.C. Bast, W.N. Halit (Eds.).
33. Buzaid A.C., Anderson C.M. The changing prognosis of melanoma. Curr Oncol Rep 2000, 2:322.
34. Gershenwald J.E., Colome M.I., Lee J.E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998, 16:2253.
35. Gershenwald J.E., Fischer D., Buzaid A.C. Clinical classification and staging. Clin Plast Surg 2000, 27:361.
36. White R.R., Stanley W.E., Johnson J.L., et al. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002, 235:879.
37. Balch C.M., Gershenwald J.E., Soong S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452.
38. McMasters K.M., Noyes R.D., Reintgen D.S., et al. Lessons learned from the sunbelt melanoma trial. J Surg Oncol 2004, 86:212.
39. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307.
40. Scolyer R.A., Murali R., Satzger I., et al. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol 2008, 17:165.
41. Balch C., Soong S., Murad T., et al. A multifactorial analysis of melanoma: prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981, 193:377.
42. Cascinelli N., Bufalino R., Marolda R., et al. Regional nonnodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986, 12:175.
43. Day C.L., Harrist T.J., Gorstein F., et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981, 194:108.
44. Leon P., Daly J.M., Synnestvedt M., et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991, 126:1461.
45. Pawlik T.M., Ross M.I., Thompson J.F., et al. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005, 23:4588.
46. Barth A., Wanek L.A., Morton D.L. Prognostic factors in 1,521 melanoma patients with distant metastases [see comment]. J Am Coll Surg 1995, 181:193.
47. Manola J., Atkins M., Ibrahim J., et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000, 18:3782.
48. Unger J.M., Flaherty L.E., Liu P.Y., et al. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001, 91:1148.
49. Eton O., Legha S.S., Moon T.E., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998, 16:1103.
50. Ryan L., Kramar A., Borden E. Prognostic factors in metastatic melanoma. Cancer 1993, 71:2995.
51. Bedikian A.Y., Johnson M.M., Warneke C.L., et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008, 26:624.
52. Keilholz U., Martus P., Punt C.J., et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002, 38:1501.
53. Sirott M.N., Bajorin D.F., Wong G.Y., et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993, 72:3091.
54. Balch C.M. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992, 8:400.
55. Staudt M., Lasithiotakis K., Leiter U., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010, 102:1213.
56. Choi M., Fuller C.D., Thomas C.R., et al. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol 2008, 109:203.
57. Fuller C.D., Wang S.J., Thomas C.R., et al. Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer 2007, 109:1331.
58. Henson D.E., Ries L.A., Carriaga M.T. Conditional survival of 56,268 patients with breast cancer. Cancer 1995, 76:237.
59. Kato I., Severson R.K., Schwartz A.G. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer 2001, 92:2211.
60. Merrill R.M., Bird J.S. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control 2002, 13:435.
61. Merrill R.M., Henson D.E., Ries L.A. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum 1998, 41:1097.
62. Wang S.J., Emery R., Fuller C.D., et al. Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer 2007, 10:153.
63. Wang S.J., Fuller C.D., Emery R., et al. Conditional survival in rectal cancer: a SEER database analysis. Gastrointest Cancer Res 2007, 1:84.
64. Bowles T.L., Xing Y., Hu C.Y., et al. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 2010, 17:2015.
65. Rueth N.M., Groth S.S., Tuttle T.M., et al. Conditional survival after surgical treatment of melanoma: an analysis of the surveillance, epidemiology, and end results database. Ann Surg Oncol 2010, 17:1662.
66. Xing Y., Chang G.J., Hu C.Y., et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010, 116:2234.
67. Soong S.J., Ding S., Coit D., et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 2010, 17:2006.
68. Hingorani S.R., Jacobetz M.A., Robertson G.P., et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63:5198.
69. Jiang X., Zhou J., Yuen N.K., et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008, 14:7726.
70. Sumimoto H., Miyagishi M., Miyoshi H., et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004, 23:6031.
71. Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
72. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809.
73. Hodi F.S., Friedlander P., Corless C.L., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046.
74. Jonsson G., Busch C., Knappskog S., et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010, 16:3356.
75. Philippidou D., Schmitt M., Moser D., et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010, 70:4163.
76. Rother J., Jones D. Molecular markers of tumor progression in melanoma. Curr Genomics 2009, 10:231.